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In Brief
Sequencing analysis of 200 Lassa virus
genomes reveals its ancient origins and
distinct evolutionary features compared
to the Ebola virus.
ArticleClinical Sequencing Uncovers Origins
and Evolution of Lassa Virus
Kristian G. Andersen,1,2,3,21,* B. Jesse Shapiro,1,2,4,21 Christian B. Matranga,2,21 Rachel Sealfon,2,5 Aaron E. Lin,1,2
Lina M. Moses,6 Onikepe A. Folarin,7,8 Augustine Goba,9 Ikponmwonsa Odia,7 Philomena E. Ehiane,7 MambuMomoh,9,10
Eleina M. England,2 Sarah Winnicki,1,2 Luis M. Branco,11 Stephen K. Gire,1,2 Eric Phelan,2 Ridhi Tariyal,2 Ryan Tewhey,1,2
Omowunmi Omoniwa,7 Mohammed Fullah,9,10,23 Richard Fonnie,9,23 Mbalu Fonnie,9,23 Lansana Kanneh,9
Simbirie Jalloh,9 Michael Gbakie,9 Sidiki Saffa,9,23 Kandeh Karbo,9 Adrianne D. Gladden,2 James Qu,2
Matthew Stremlau,1,2 Mahan Nekoui,1,2 Hilary K. Finucane,2 Shervin Tabrizi,1,2 Joseph J. Vitti,1 Bruce Birren,2
Michael Fitzgerald,2 Caryn McCowan,2 Andrea Ireland,2 Aaron M. Berlin,2 James Bochicchio,2 Barbara Tazon-Vega,2
Niall J. Lennon,2 Elizabeth M. Ryan,2 Zach Bjornson,12 Danny A. Milner, Jr.,13 Amanda K. Lukens,13 Nisha Broodie,14
Megan Rowland,11 Megan Heinrich,11 Marjan Akdag,11 John S. Schieffelin,6 Danielle Levy,6 Henry Akpan,15
Daniel G. Bausch,6 Kathleen Rubins,16 Joseph B. McCormick,17 Eric S. Lander,2 Stephan Gu¨nther,18 Lisa Hensley,19
Sylvanus Okogbenin,7 Viral Hemorrhagic Fever Consortium,20 Stephen F. Schaffner,2 Peter O. Okokhere,7
S. Humarr Khan,9,23 Donald S. Grant,9 George O. Akpede,7 Danny A. Asogun,7 Andreas Gnirke,2 Joshua Z. Levin,2,22
Christian T. Happi,7,8,22,* Robert F. Garry,6,22 and Pardis C. Sabeti1,2,13,22,*
1FAS Center for Systems Biology, Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA 02138, USA
2Broad Institute, Cambridge, MA 02142, USA
3The Scripps Research Institute, Scripps Translational Science Institute, La Jolla, CA 92037, USA
4Department of Biological Sciences, University of Montre´al, Montre´al, QC H2V 2S9, Canada
5Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
6Tulane Health Sciences Center, Tulane University, New Orleans, LA 70118, USA
7Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State, Nigeria
8Department of Biological Sciences, College of Natural Sciences, Redeemer’s University, Redemption City, Osun State, Nigeria
9Lassa Fever Laboratory, Kenema Government Hospital, Kenema, Eastern Province, Sierra Leone
10Eastern Polytechnic College, Kenema, Eastern Province, Sierra Leone
11Zalgen Labs, Germantown, MD 20876, USA
12Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94304, USA
13Department of Immunology and Infectious Disease, Harvard School of Public Health, Boston, MA 02115, USA
14College of Medicine, Columbia University, New York, NY 10032, USA
15Nigerian Federal Ministry of Health, Abuja, Federal Capital Territory, Nigeria
16The National Aeronautics and Space Administration, Johnson Space Center, Houston, TX 77058, USA
17The University of Texas School of Public Health, Brownsville, TX 77030, USA
18Department of Virology, Bernhard-Nocht-Institute for Tropical Medicine, 20259 Hamburg, Germany
19NIAID Integrated Research Facility, Frederick, MD 21702, USA
20Tulane University, New Orleans, LA 70118, USA
21Co-first author
22Co-senior author
23Deceased
*Correspondence: andersen@scripps.edu (K.G.A.), happic@run.edu.ng (C.T.H.), psabeti@oeb.harvard.edu (P.C.S.)
http://dx.doi.org/10.1016/j.cell.2015.07.020SUMMARY
The 2013–2015 West African epidemic of Ebola
virus disease (EVD) reminds us of how little is known
about biosafety level 4 viruses. Like Ebola virus,
Lassa virus (LASV) can cause hemorrhagic fever
with high case fatality rates.We generated a genomic
catalog of almost 200 LASV sequences from clinical
and rodent reservoir samples.We show that whereas
the 2013–2015 EVD epidemic is fueled by human-to-
human transmissions, LASV infections mainly result
from reservoir-to-human infections. We elucidated
the spread of LASV across West Africa and show
that this migration was accompanied by changes
in LASV genome abundance, fatality rates, codon738 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.adaptation, and translational efficiency. By investi-
gating intrahost evolution, we found that mutations
accumulate in epitopes of viral surface proteins, sug-
gesting selection for immune escape. This catalog
will serve as a foundation for the development of vac-
cines and diagnostics.
INTRODUCTION
Viruses that cause human hemorrhagic fevers, such as Ebola,
Marburg, and Lassa, are classified as BL-4 agents due to their
high fatality rates and lack of effective treatment (Paessler and
Walker, 2013). With increasing globalization, changing climatic
conditions and an ever-expanding human population, our inter-
actions with these pathogens are likely to increase (Gire et al.,
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Figure 1. Lassa Fever Is a Viral Hemorrhagic Fever Endemic in West Africa, where Ebola Virus Disease Broke Out in 2014
(A) Overview of the LF endemic zone. Study sites are marked. The LF risk zone was defined according to Fichet-Calvet and Rogers (2009).
(B) Schematic of LASV virions.
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See also Figure S1, Tables S1 and S2, and Data S1.2012; Lipkin, 2013). The 2013–2015 Ebola virus disease (EVD)
epidemic (Baize et al., 2014) is a stark reminder that a better
understanding of these viruses is required to develop effective
therapeutics and vaccines, as standard containment and isola-
tion can be insufficient to prevent large-scale outbreaks (Pandey
et al., 2014).
Lassa virus (LASV) is unique among BL-4 agents in being a
common human pathogen, causing endemic disease in much
of West Africa, primarily in Sierra Leone, Guinea, Liberia, and
Nigeria (Figure 1A). Infection with LASV can lead to acute Lassa
fever (LF) with symptoms similar to EVD. LASV is estimated to
hospitalize tens of thousands and cause several thousand
deaths each year. Case fatality rates (CFRs) among hospitalized
LF patients can exceed 50%, although numerous sub-clinical in-
fections are believed to occur (Troup et al., 1970; McCormick
and Fisher-Hoch, 2002). Most patients are infected by exposure
to excreta from the rodentMastomys natalensis, which functions
as a reservoir and maintains persistent infections (Lecompte
et al., 2006); human-to-human transmissions have also been re-
ported, however, primarily in hospital settings (McCormick and
Fisher-Hoch, 2002; Lo Iacono et al., 2015).
LASV is a single-stranded RNA virus in the family Arenavir-
idae. Its genome consists of two segments, L (7.3 kb) and
S (3.4 kb), which encode four proteins: Z (matrix), L (polymer-
ase), NP (nucleoprotein), and GPC, which is post-translation-
ally cleaved into two peptides, GP1 and GP2, that form the
transmembrane glycoprotein (Figure 1B). EBOV (Zaire ebola-
virus) is a single-stranded RNA virus in the family Filoviridaewith a 19-kb genome encoding seven proteins. While the
prevalence of LASV makes it a rare model for studying the
evolution of a BL-4 pathogen, only 12 whole-genome LASV
sequences were available prior to this study (Djavani et al.,
1997; Vieth et al., 2004).
RESULTS
Generation of a Large Dataset of Lassa Virus Genomes
We established partnerships with Kenema Government Hospital
(KGH), Sierra Leone, and Irrua Specialist Teaching Hospital
(ISTH), Nigeria, and collected samples from LF patients between
2008 and 2013.We implemented diagnostics, training, and infra-
structure to ensure high-quality and safe sample collection from
patients hospitalized with LF (Shaffer et al., 2014).
We sequenced 183 LASV genomes from these clinical
samples, 11 LASV genomes from M. natalensis field samples,
and two genomes from viral laboratory isolates (Figure 1C; Ta-
ble S1); we deposited all sequence data at NCBI (BioProject
PRJNA254017) before publication. Most samples contained
>50% human material and yielded <1% LASV reads (Figures
S1A and S1B; Table S1). Genome coverage was fairly uniform,
with higher coverage of the S than the L segment (Figure 1D),
consistent with a greater copy number of S (Southern, 1996).
Since we used an unbiased sequencing approach, we were
also able to assemble 7,028 unique open reading frames from
the transcriptome of M. natalensis, a species not previously
sequenced (Figures S1C–S1E; Data S1).Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc. 739
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Figure 2. LASV Is More Diverse than EBOV and Has Ancient Origins in Nigeria
(A) Phylogenetic tree of LASV S segments (n = 211) (outer ring: gray, previously sequenced; orange, sequenced from M. natalensis; scale bar, nucleotide
substitutions/site; I–IV, lineages as defined by Bowen et al. (2000).
(B) Scaled trees of LASV L and S segments, as well as EBOV. Trees are shown with the same scale of genetic distance (0.1 nucleotide substitutions/site), except
for EBOV, which was magnified 103 (0.01 nucleotide substitutions/site). LASV lineages are shown (Nig., Nigeria; MRU, Mano River Union).
(C and D) Root-to-tip distance versus collection date for (C) EBOV from the West African EVD epidemic (2014; n = 131) or (D) LASV from Sierra Leone (2012;
n = 21). Confidence intervals (95%) for linear regression fits are shown in blue.
(E) The%pairwise differences (log scale) in EBOV lineages from the 2014 EVD epidemic (March–October 2014; n = 116) and LASV lineages fromSierra Leone (SL;
2009–2013; n = 60) and Nigeria (NG; 2009–2012; n = 83). The % divergence was calculated within the countries for each year separately and pooled. Error bars
represent SD.
(F–H) Bayesian coalescent analysis of LASV samples (matched dataset, n = 179). (F) Substitution rates. (G) LASV L segment tMRCA for each country (median
values; ya, years ago). Gray arrows depict the likely spread of LASV. An asterisk indicates a tMRCA that was dependent on only one sequence (AV) from outside
Nigeria and MRU. (H) Probability distributions for the estimated tMRCAs with median marked.
See also Figures S1F–S1H, S2, S3, S4, and S5, Table S2, and Data S1, S2, and S3.Lassa Virus Strains Are Genetically Diverse and Cluster
Based on Geographic Location
We first examined patterns of variation and phylogenetic rela-
tionships. We found high levels of LASV nucleotide diversity,
with strain variation up to 32%and 25% for the L andS segments
(Figures 2A, S1F, and S1G). This is substantially higher than pre-
vious findings based on LASV fragments (Bowen et al., 2000),
andmuch higher than EBOV, which is more than 97% conserved
across all sequenced strains (Figures 2B and S1H). We
confirmed previous findings (Bowen et al., 2000) that LASV
clusters into four major clades: three in Nigeria and one from740 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.the Mano River Union countries (MRU) of Sierra Leone, Guinea,
and Liberia (Figure 2A; Data S1, S2, and S3). We found no evi-
dence for host-specific clades of LASV lineages; rather, samples
from humans and M. natalensis clustered together (Figure 2A;
Data S1, S2, and S3). We did not identify any recombination
events within segments, but did find evidence for reassortment
between segments in three samples (Figures S2A–S2G). This
could be explained by infections of individual hosts with multiple
LASV lineages, followed by shuffling of segments, a process
previously observed in vitro with LASV (Lukashevich, 1992) and
in vivo with other arenaviruses (Stenglein et al., 2015).
Lassa Virus Infections Are the Result of Multiple
Independent Reservoir-to-Human Transmissions
Recent studiessuggest that the2013–2015EVDepidemic ismain-
tained by sustained human-to-human transmission (Gire et al.,
2014) after an initial ‘‘spillover’’ event from a likely animal reservoir
(Baize et al., 2014). Similarly, it has been suggested that up to 20%
of LF cases also arise from human-to-human transmissions (Lo
Iacono et al., 2015). Sustained human-to-human transmission
should result in a ‘‘ladder-like’’ structure of the phylogenetic tree
along with a strong correlation between a sample’s collection
date and its genetic distance from the root of the tree over a short
time period. Based on data from the 2013–2015 EVD epidemic
(Team, 2014), we defined that time period as one year. While
collection date is strongly correlated with root-to-tip distance for
EBOV from the 2013–2015 EVD epidemic (R2 = 0.64; Figure 2C;
Table S2), the same correlation is absent for LASV sampled over
a similar time period (R2 = 0.0001; Figure 2D; Table S2).
Human-to-human transmission should also result in clustering
of contemporaneous viral sequences on the tree. While this is
pervasive across the 2013–2015 EVD epidemic samples (Gire
et al., 2014) (Data S1), we found that only 5 out of 169 (3%)
LASV sequences from patients resulted in such clusters (Data
S1 and S3). As M. natalensis serves as the reservoir host for
LASV—and presumably maintain LASV diversity via sustained
rodent-to-rodent transmission chains—we would expect rodent
samples to group into more defined clusters. Indeed, 5 out of 10
(50%) LASV sequences from M. natalensis formed clusters
consistent with rodent-to-rodent transmissions (Data S1 and
S3). Finally, we also found that the average pairwise divergence
for EBOV lineages in Sierra Leone from the 2013–2015 EVD
epidemic was much lower than that observed for LASV lineages
within individual years from Sierra Leone (Figure 2E), despite
similar observed substitution rates (Figure 2F). These three lines
of evidence suggest that, while EBOV during the 2013–2015 EVD
epidemic was transmitted through human-to-human contact,
most human LASV infections represent independent transmis-
sions from a genetically diverse reservoir.
Lassa Virus Has Ancient Origins in Modern-Day Nigeria
and Has Recently Spread across West Africa
While EBOV and LASV were both discovered in the latter part
of the 20th century—1976 and 1969, respectively—their origins
likely vary greatly (Commission, 1978; Frame et al., 1970).
Reports suggest that all EVD outbreaks share a common
ancestor within the last fifty years (Carroll et al., 2013; Dudas
and Rambaut, 2014; Calvignac-Spencer et al., 2014; Gire
et al., 2014). In contrast, the widespread persistence of LASV
in M. natalensis, and evidence in the human genome of natural
selection linked to LASV resistance (Andersen et al., 2012), sug-
gest that LASV might be a long-standing human pathogen.
Usingmolecular dating, we found that extant LASV strains likely
originated inmodern-dayNigeriamore than a thousand years ago
and spread into neighboringWest African countries within the last
several hundred years (Figures 2G and 2H). We first examined
evidence for a molecular clock by comparing sample collection
dates and root-to-tip distances across the entire LASV tree. In
contrast to the shorter timescales analyzed above (Figure 2D),
here we found significant evidence for a molecular clock (R2 =0.38, p value < 0.0001). This allowed us to calculate the time
to the most recent common ancestor (tMRCA) using Bayesian
coalescent analysis (Drummond et al., 2012). We estimated the
tMRCA of sampled extant LASV strains to be a little over one
thousand years for the L segment (FigureS2H; Table S2;median=
1,057 years ago [ya]; 915 ya–1,218 ya; 95% highest posterior
density [HPD]) and 650 years for the S segment (Figure S2I; Table
S2; median = 631 ya; 519 ya–748 ya, 95% HPD). While LASV
strains inNigeria have the same tMRCA as all extant strains, those
in Sierra Leone have an estimated tMRCA of only 150 years (Fig-
ures 2G and 2H; median = 153 ya; 137 ya–171 ya; 95% HPD).
We tested the sensitivity of our results to key analysis param-
eters that could severely affect our tMRCA estimates (Wertheim
and Kosakovsky Pond, 2011; Wertheim et al., 2013). We found
that our estimates were robust to the choice of all tested param-
eters, including evolutionary model, geographical separations,
and exclusion or inclusion of older ‘‘anchoring’’ sequences,
e.g., the 1969 Pinneo strain (Figures S3 and S4; Table S2). In
linear regression of root-to-tip distance of samples on the date
of collection, the sequences from theMRU showed the strongest
evidence of temporal structure, suggesting that the dating is
most reliable within that region (Figure S4).
Non-Nigerian Lassa Virus Strains Have Higher Codon
Adaptation to Mammalian Hosts
Previous studies have shown that viruses can adapt their codon
usage to that of their hosts for translational efficiency (Sharp and
Li, 1987; Bahir et al., 2009; Butt et al., 2014; Hershberg and
Petrov, 2008). We examined the codon adaptation index (CAI)
of LASV and EBOV to different hosts. CAI quantifies how well
synonymous codon choice in the viral genome matches that of
a potential host genome.
We found that LASV had a higher mean CAI than EBOV, and a
similar CAI distribution across different potential mammalian
hosts (Figure 3A). There was a strong linear correlation between
the CAI of LASV to human and to M. natalensis, regardless of
which organism LASV was sequenced from (Figure S5A). In
agreement with previous studies (Bahir et al., 2009), this
suggests that codon adaptation to one mammal also leads to
adaptation to another.
We also compared LASV sequences from patients in Sierra
Leone to those fromNigeria and found that the former had signif-
icantly higher CAI (p value < 0.001, permutation test) (Figure 3B).
This apparent ‘‘burst’’ of codon adaptation as LASV spread into
Sierra Leone began on the branch leading out of Nigeria and
remained high in most non-Nigerian strains (Figures 3C, 3D,
and S5B–S5E), with an even distribution across the LASV
genome (Figure S5F).
As it has been suggested that dinucleotide usage play a role in
determining translational efficiency of RNA viruses (Tulloch et al.,
2014), we investigated whether there was a difference between
Nigerian and Sierra Leonean strains, but did not observe any sig-
nificant skew (Figures S5G and S5H).
Lassa VirusGenomeAbundance andCase Fatality Rates
Differ between Nigeria and Sierra Leone
Increased codon optimization might lead to increased viral
output (Plotkin and Kudla, 2011) and therefore higher viral titersCell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc. 741
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Figure 3. Increased Codon Adaptation of
Non-Nigerian LASV Strains
(A) Codon adaptation index (CAI) of individual
LASV (orange) and EBOV (gray) sequences to four
mammalian hosts, normalized by GC and amino
acid content.
(B) Normalized CAI (to human) of LASV sequences
plotted against their distance (aa substitutions/
site) to the root of the tree. (C) Phylogeny of the
LASV L genes (scale bar, substitutions/site). (D) A
phenogram depicting the phylogeny from (C) with
branch lengths representing CAI (scale bar, con-
verted Z score).
(C and D) Trees were rooted on Pinneo (data not
shown; batch 1 dataset).
See also Table S2.(Lauring et al., 2012) for non-Nigerian strains. With standardized
inclusion criteria at our field sites (Supplemental Experimental
Procedures), we tested this hypothesis by using qPCR to quan-
tify LASV genome abundance.We found significantly more LASV
genomes in patients fromSierra Leone than in those fromNigeria
(Figure 4A). LASV genome abundance in Sierra Leone was
similar to that observed in EBOV patients from the same hospital
(KGH; Figure 4A) and decreased over the course of the infection
(Figure S5I), likely due to treatment with the antiviral drug ribavirin
(McCormick et al., 1986). Next, we binned the LASV samples into
those in the top or bottom 50% CAI from within each country,
and compared LASV genome abundance between bins. In Sierra
Leone, individual LASV sequences with high CAI tended to have
higher genome copy numbers (p value < 0.05, Mann-Whitney
test) but no trend was visible in Nigeria (Figures 4B and 4C).
This suggests that CAI may affect LASV replication rate and
abundance.
Since increased viremia of LASV in LF patients is correlated
with higher fatality rates (McCormick and Fisher-Hoch, 2002),
we might also expect CFRs to be higher in patients from Sierra
Leone than from Nigeria. Again using strict criteria for inclusion,
we found a significantly higher CFR (p value = 0.01; Fisher’s
exact test) in Sierra Leonean patients than in their Nigerian coun-
terparts (81% versus 60%; Figure 4D). While the treatment op-
tions for LF patients are similar in the two countries, other factors
could also affect genome abundances and CFRs. In particular,
delay in clinical care could bias our estimates; however, self-742 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.reported times from onset of symptoms
to hospital admission are the same in
the two countries (average = 9.3 days;
Figure 4E).
Nigerian Lassa Virus Strains Have
Higher Protein Output than Do
Sierra Leonean Strains
Although we observed a correlation
among CAI, viral genome abundance,
and CFR, it remained unclear whether
this is driven by differences in protein
translation efficiency between Nigerian
and Sierra Leonean LASV strains. We de-signed an experimental system to estimate translational activity
for a single LASV gene with different CAI values. We randomly
selected 20 LASV sequences from Nigeria and Sierra Leone
and fused the first 699 bp of their NP genes (NP1–699) to lucif-
erase, before cloning into expression vectors for transfection
or in vitro translation experiments (Figure 4F). Readout of lucif-
erase activity allowed us to detect differences in translational
activity of the chimeric transcripts. As controls, we codon-opti-
mized one LASV sequence from Nigeria and one from Sierra
Leone, for an upper bound on NP1–699-luciferase translational
efficiency.
For both transfection and in vitro translation experiments, we
observed a significant difference in translational output of the
tested NP1–699-luciferase genes, with Nigerian versions having
higher outputs (Figures 4G and 4H). This was the opposite of
the expectation based on CAI because the Sierra Leonean
sequences had higher CAI (Table S2). Nigerian versions also
had higher outputs for the codon-optimized forms of NP1699
(Figure 4H), suggesting that Nigerian sequences are intrinsically
more efficient or stable.
To test whether these observations were specific to NP, we
repeated the in vitro translation experiment using the first
736 bp of ten LASV GPC genes (Figure 4F). Once again, we
found that Nigerian genes had significantly higher translational
output (Figure 4I). These results suggest that there is a difference
in the translational output between LASV strains from Nigeria
and Sierra Leone that is independent of the variation in CAI.
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Figure 4. Difference in Viral Output between Nigerian and Sierra Leonean LASV Strains
(A) Relative abundance of LASV and EBOV genome copies (log ratio of LASV or EBOV copies/microliter to 18S rRNA copies/microliter; ***p < 0.001, Mann-
Whitney test).
(B and C) Relative abundance of LASV genome copies when partitioned into sequences in the top or bottom half of CAI scores. (B) Samples from Nigeria.
(C) Samples from Sierra Leone (*p value < 0.05, Mann-Whitney test).
(D) Case fatality rates calculated for patients from Sierra Leone (n = 67) and Nigeria (n = 40). p value from Fisher’s exact test.
(E) Patient-reported days from the onset of symptoms until admission to the hospital. The mean values are displayed with red bars.
(F) DNA plasmids encoding the first 699 nucleotides of LASV NP or the first 736 nucleotides of LASV GPC.
(G) NP-reporter expression was measured in HEK293 cells by the ratio of fLuc/rLuc 20 hr post-transfection.
(H and I) In vitro transcription of (H) NP- or (I) GPC-reporter translation measured by gLuc luminescence after 21 hr.
All values were normalized to the average of each biological replicate (n = 3) (G–I). *p < 0.05, ***p < 0.0001, Mann-Whitney test; NG, Nigeria, SL, Sierra Leone.
See also Table S2.Lassa Virus Is a More Diverse Intrahost than Is
Ebola Virus
The long-term evolution of viruses ultimately depends on muta-
tion and selection within individual hosts (Parameswaran et al.,
2012). Our deep sequencing allowed us to examine LASV intra-
host single-nucleotide variants (iSNVs) within individual human
and rodent hosts (Figure 5A). We called variants at a minimum
minor allele frequency (minMAF) of 5% and applied stringent
filtering (Supplemental Experimental Procedures). We validated
subsets of iSNVs using different sequencing technologies and
found that our results were consistent across platforms, experi-mental replicates, library preparations, and variant calling
methods (Figures S5J–S5L and S6).
We found that M. natalensis generally harbors more LASV
iSNVs than humans (median iSNVs/kb = 1.5 versus 0.1; p value <
0.0001; Mann-Whitney test), consistent with longer, more
chronic infections (Figures 5B and S7A–S7D). LASV is a signifi-
cantly more diverse intrahost than is EBOV (accounting for dif-
ferences in sequence coverage between the two; median bp
coverage 2,0003 for EBOV [Gire et al., 2014] and 2503 for
LASV; Figure 1C; p value = 0.0005; Mann-Whitney test), with
an average number of iSNVs per covered site of 2.1 3 103 inCell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc. 743
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Figure 5. Genetic Diversity and Selective
Pressures within and between Hosts
(A) iSNVs can be detected in Illumina reads.
(B) The number of iSNVs at 5% MAF or higher,
called in LASV (orange) and EBOV (gray).
(C) The normalized number of iSNVs per covered
site (80% calling power; 5% MAF). In both (B) and
(C), each circle represents one LASV or EBOV
sample; red bars denote the median; ***p < 0.001,
Mann-Whitney test; ns, not significant. Only sam-
ples with >503 coverage are included.
(D) dN/dS ratios for LASV and EBOV based
on iSNVs or fixed differences in consensus
sequences between hosts.
(E) dN/dS ratios for each LASV gene.
***p < 0.001, **p < 0.01, Permutation test; ns = not
significant (D and E). The very short Z gene was
excluded.
See also Figures S6 and S7, Table S2, and
Data S1.LF patients, but only 1.33 104 in EVD patients (Figure 5C). This
difference is primarily driven by a subset of LASV-infected indi-
viduals that have >15 iSNVs—diversity similar to that observed
in M. natalensis (Figure 5C). Such high diversity—with iSNV
frequencies that appear stable over the course of infection
(Figure S7E)—was never observed in EVD patients (Figures 5B
and 5C).
LF is generally considered an acute disease in humans
(McCormick and Fisher-Hoch, 2002), but high numbers of iSNVs
could be explained by long-term chronic infections and/or adap-
tive evolution of LASV. An alternative explanation is multiple
infections; however, the wide range of allele frequencies (Fig-
ure S7F) and general lack of linkage between iSNVs (Table S2)
argues against this being the prevailing explanation. In addition,
the vast majority of iSNVs (94.4%) are transitions, rather than
transversion mutations (Figure S5L), which accumulate over
longer evolutionary timescales (Wakeley, 1996). This suggests
that most iSNVs are evolutionarily recent and that LASV iSNVs
arise mostly via de novo mutation within hosts, and more rarely
via transmission and multiple infections by circulating strains.
Natural Selection Is Acting on the Lassa Virus
Glycoprotein
Next, we investigated the role of natural selection in shaping in-
trahost variation. In LASV, we observed a significantly higher dN/
dS (p value = 0.0013; permuted McDonald-Kreitman test)—a
measure of selective constraint at the protein level—within hosts
than between hosts (Figure 5D). For EBOV, the trend was in the
same direction but was not statistically significant (Figure 5D).
Assuming that dN represents mostly deleterious mutations (Sha-744 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.piro et al., 2009), this is consistent with
these mutations being purged by purify-
ing selection over evolutionary time
(Rocha et al., 2006). Because purifying
selection has less time to act within a
single host, dN/dS is higher within hosts
than between. However, the dN/dS of
0.2 for LASV iSNVs is still much less
than 1 expected in the absence of any selection (Anisimova
and Liberles, 2007). In contrast, iSNVs in certain other viruses,
such as dengue, approach the neutral expectation of dN/dS
1 (Holmes, 2003). Also, reflecting purifying selection on LASV
within hosts, the dN/dS ratio appears to decrease at higher
iSNV frequencies (Figure S7G). EBOV intrahost dN/dS is higher
than LASV (Figure 5D), consistent with LASV intrahost popula-
tions being subject to stronger (or a longer duration of) purifying
selection.
Intrahost dN/dS varied widely across LASV genes, suggesting
different selective pressures on individual genes. Most notably,
GPC genes sequenced from both human and M. natalensis,
had a significantly higher dN/dS ratio within hosts than between
hosts (Figure 5E). GPC encodes the only protein partially
exposed on the outside of the LASV particle (Figure 1B). It has
a significantly higher within-host dN/dS than does NP (p value <
0.05; Fisher’s exact test), the neighboring gene on the S segment
(Figure 5E), but similar between-host dN/dS. These results
suggest either a GPC-specific relaxation of within-host purifying
selection or within-host diversifying (positive) selection (Baum
et al., 2003).
Nonsynonymous Lassa Virus Intrahost Variants
Accumulate in Predicted Epitopes in the Glycoprotein
We hypothesized that immune pressures on LASV GPC could
drive within-host diversifying selection, favoring nonsynony-
mous iSNVs that impair immune detection by disrupting epi-
topes. This phenomenon has been reported for other viruses;
e.g., at the population-wide level in pandemic influenza A virus
(Bhatt et al., 2011). To evaluate whether iSNVs disrupt epitopes,
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Figure 6. Nonsynonymous iSNVs Are Overrepresented within Predicted B Cell Epitopes in LASV GPC
(A) The fraction of iSNVs within predicted B cell epitopes. The observed fraction is compared to the expected fraction (**p < 0.01, *p < 0.05, binomial test).
(B) Overlap between GPC epitopes and iSNVs. Epitopes were predicted separately in each sample (y axis) and overlaid with iSNVs from that sample.
(C) Fraction of iSNVs falling within predicted T cell epitopes (p value = binomial test).
(D and E) Binding of monoclonal antibodies (mAbs) to iSNV mutants in predicted B cell epitopes was tested in HEK293 cells. (D) Each circle corresponds to the
normalized average mean fluorescence intensity (MFI) measured by flow cytometry of each LASV GPC construct carrying either wild-type or iSNV mutations
(Supplemental Experimental Procedures). Each tested mAb is shown on the x axis. The MFI was normalized to the MFI of the empty vector control for each
experiment. (E) Binding to the GP1-specific mAbs 12.1F and 19.7E using constructs carrying either the major or minor population-wide allele at positions 89 and
114. For comparison, binding to mAb 36.1F, which requires GP2, is also shown. All MFI values are normalized to the MFI of binding to the GP2-specific mAb
37.2D. Error bars show the SD from four independent experiments; *p < 0.05, Mann-Whitney test.
See also Table S2 and Data S1.we used a machine-learning method (El-Manzalawy et al., 2008)
to predict linear B cell epitopes in each LASV protein.
Nonsynonymous iSNVs in LASV GPC occurred in predicted B
cell epitopes significantly more than expected by chance (Fig-
ures 6A and 6B; p value < 0.01; binomial test). This was true
for LASV samples from patients and M. natalensis indepen-
dently, although the signal was stronger in patients (Figure 6A).
In contrast, synonymous iSNVs were randomly distributed
across GPC, consistent with their lack of impact on epitope
structure (Figures 6A and 6B). We observed a similar but weaker
trend for NP, although this difference only reached statistical
significance in M. natalensis (Figure 6A).
To test if nonsynonymous iSNVs interfere with B cell epitope
recognition, we reran the B cell epitope predictions, changing
single amino acids within the epitopes from the consensus call
to the iSNV variant. For 14 of the 18 predicted B cell epitopes,
changing the iSNV from the consensus to the variant allele signif-icantly reduced the epitope score (Table S2; p value = 0.015,
Sign test).
To test if nonsynonymous iSNVs also appear to fall within T cell
epitopes, we predicted T cell epitopes in each LASV protein
(Supplemental Experimental Procedures). We found that nonsy-
nonymous iSNVs accumulated to some extent in LASV GPC,
although the results did not reach statistical significance (Fig-
ure 6C; p value = 0.07; binomial test).
Intrahost Variants Interfere with Antibody Binding
To investigate the functional effects of a subset of LASV iSNVs,
we created iSNV mutations in predicted B cell epitopes in GP1
(Supplemental Experimental Procedures), expressed them in
HEK293 cells, and tested their binding to a panel of GPC-specific
monoclonal antibodies (mAbs) using flow cytometry. These mu-
tations led to a significant drop in the averagemean fluorescence
intensity (MFI) for GP1-specific mAbs (Figure 6D), consistentCell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc. 745
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See also Figure S7H and Table S2.with diminished mAb binding. Similarly, when we investigated
the effects of single-point mutations within GP1 epitopes, we
found that minor alleles in the LASV population displayed signif-
icantly reduced binding to GP1-specific mAbs (Figure 6E).
These observations suggest that the host adaptive immune
system imposes selective pressures on the intrahost viral popu-
lation, driving an accumulation of nonsynonymous iSNVs in
LASV GPC.
Nonsynonymous Lassa Virus Intrahost Variants Tend
Not to Become Fixed in Other Hosts
To further explore the evolution of LASV within and between
hosts, we investigated how often iSNVs become fixed in other
consensus sequences.We defined an iSNV as ‘‘fixed’’ if its minor
allelic variant was observed in one or more LASV consensus se-
quences. We observed a significantly higher nonsynonymous-
to-synonymous ratio (N/S) for unfixed compared to fixed iSNVs
(Figure 7A), suggesting a selective bias against the fixation
of nonsynonymous iSNVs. LASV and EBOV both have similar
numbers of unfixed iSNVs, but LASV has many more fixed
iSNVs, likely due to higher rates of iSNV fixation (or transmission)
in LASV than in EBOV (Figure 7B). However, the putative trans-
mitted (fixed) iSNVs tend to be biased toward synonymous mu-
tations. This bias is much stronger in LASV (Figure 7C, top) but
still detectable in EBOV (Figure 7C, middle). The bias cannot
be attributed to differences in minor allele frequencies between
nonsynonymous and synonymous iSNVs (p value > 0.1; Kolmo-
gorov-Smirnov test) or to a correlation between MAF and preva-
lence in consensus sequences (p value > 0.1 for both N and S;
Pearson’s correlation); therefore, it is best attributed to selection
against transmission and/or fixation of nonsynonymous iSNVs.
A single suspected transmission event, between a pair of
M. natalensis captured on the same day from the same house-
hold, provided an opportunity to observe iSNV fixation dynamics
on short timescales. The two samples, Z0947 and Z0948, are746 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.nearest-neighbors on the LASV phylogeny (Data S1, S2, and
S3), suggesting recent (but not necessarily direct) transmis-
sion (Supplemental Experimental Procedures). Assuming that
transmission occurred from Z0948 to Z0947, we observed that
derived alleles reaching high frequency (DAF > 0.5) in Z0947
tended to be nonsynonymous, while derived alleles remaining
at lower frequency (DAF < 0.5) were always synonymous (Fig-
ure 7C, bottom). Other transmission scenarios (Figure S7H;
Supplemental Experimental Procedures) also confirm that non-
synonymous iSNVs reach high frequency within a host, but fail
to be transmitted to the next host. Along with the dN/dS and
epitope analyses, this supports a model in which nonsynony-
mous iSNVs rise to high frequency within an individual due to
positive selection, but are less likely to become fixed in other
hosts due to purifying selection.
DISCUSSION
Comparing Ebola Virus and Lassa Virus Evolutionary
Dynamics
EBOV and LASV are RNA viruses that can lead to illnesses with
similar clinical symptoms, yet they differ markedly in their epide-
miology and evolutionary dynamics. LASV is more than an order
of magnitude more diverse than EBOV (Figure 2B), and molecu-
lar dating suggests that it has been circulating in Nigeria for over
a thousand years, followed by amore recent spread acrossWest
Africa (Figure 2G). In contrast, it has been suggested that the
Makona variant of EBOV responsible for the EVD epidemic in
West Africa was introduced over the last decade (Dudas and
Rambaut, 2014; Calvignac-Spencer et al., 2014; Gire et al.,
2014).
These analyses, however, provide lower-bound tMRCA esti-
mates of sampled (extant) viral lineages; the true ages of all
LASV and EBOV lineages are likely much older (Taylor et al.,
2010). Because of limited sampling from Guinea and Liberia,
our LASV dating analysis is likely most accurate within
Sierra Leone, although we achieved comparable results when
considering the entire dataset or the individual regions alone
(Figure S3E). Furthermore, our 400-year-old ‘‘out of Nigeria’’
estimate relies on a single sequence from the Ivory Coast; addi-
tional sampling outside the MRU and Nigeria could push back
this date.
Because of the high heterogeneity among LASV lineages,
continuous monitoring of its mutational spectrum and evolu-
tionary change will be critical for the development of effective
vaccines and diagnostics. Since LASV strains cluster by ge-
ography, it is more conserved within individual countries. For
example, average sequence identity among lineages from Sierra
Leone is 90% at the nucleotide level and 95% at the amino acid
level (Figure S1F). A useful strategymight therefore be to develop
diagnostics, vaccines, and sequence-specific therapeutics that
are country specific or that target the most conserved features
of the viral genome.
The 2013–2015 West African EVD epidemic likely originated
from a single zoonotic transmission event (Baize et al., 2014), fol-
lowed by sustained human-to-human transmission and clock-
like, linear accumulation of mutations (Figure 2C). In contrast,
LASV has a clock-like signature on the timescale of decades
(Figure S4B), but not on shorter timescales (Figure 2D). Com-
bined with the intermingling of human andM. natalensis samples
on the phylogenetic tree (Figure 2A), this is consistent with a
genetically diverse pool of LASV being maintained in its rodent
reservoir, with most human infections caused by genetically
distinct viruses. A recent study suggested that human-to-human
transmission of LASV may account for up to 20% of all cases
(Lo Iacono et al., 2015), but we found little support for this in
our dataset. This does not rule out human-to-human transmis-
sion entirely, but it suggests that human transmission chains
are the exception rather than the rule.
LASV is more polymorphic within hosts than EBOV, and
M. natalensis hosts harbor more polymorphic LASV populations
than humans (Figures 5B and 5C). Since most LF and EVD
patients have 0 or 1 iSNVs, the difference difference between
LASV and EBOV is mostly driven by a subset of LF patients
with many LASV iSNVs (Figure 5B and 5C). LASV iSNV
frequencies tend to remain stable over the relatively short period
of hospitalization (Figure S7E), suggesting that intrahost de novo
mutations and frequency changes may take time to develop or
may occur early in the infection. These observations suggest
that—at least in some patients—LASV infections could last
longer than EBOV infections, allowing more time for the genera-
tion of polymorphism within hosts.
Longer infections also provide more time for natural se-
lection to eliminate deleterious mutations from the viral popu-
lation. Consistent with longer infection periods in LASV, dN/dS
ratios are lower within LF patients than in EVD patients
(Figure 5D).
While these findings are consistent with the existence of
chronic LASV infections in humans, they do not constitute proof.
Further studies are needed to verify the causes of high-diversity
LASV infection and the prevalence of nonacute human infec-
tions. Compelling evidence could come from longitudinal sam-
pling asymptomatic carriers of LASV, for example.Codon Adaptation, Translational Efficiency, and
Genome Abundance
We uncovered significant differences in genome abundance,
CFR, CAI, and translational efficiency of LASV strains from Sierra
Leone and from Nigeria. The increase in CAI of non-Nigerian
strains (Figures 3B–3D), along with higher viral copy numbers
and CFRs in human patients (Figures 4A–4D), would seem to
suggest that the virus evolved toward greater human virulence.
There are indeed many examples suggesting that pathogens
with natural reservoirs may evolve toward greater human
virulence, so long as they remain avirulent in the reservoir host
(Ewald, 1994). We have not, however, been able to establish
causality among these observations. While clinical care for LF
patients is similar at ISTH and KGH (Supplemental Experimental
Procedures)—and time from symptom onset to hospitalization
appears to be the same (Figure 4E)—several additional parame-
ters are beyond our control, including variations in socioeco-
nomic, clinical, and human genetic factors between Sierra Leone
and Nigeria. These prevent us from determining whether the
difference in CFRs has a viral genetic basis and whether varia-
tions in CAI, viral genome abundance, and CFRs are causally
linked. In addition, while we observed significantly higher LASV
genome abundance in LF patients from Sierra Leone, we could
not determine whether this difference translates into higher
infectious titers. Controlled animal studies in BL-4 laboratories
comparing strains from the two countries would help to resolve
this important question.
We expected that the increased CAI of Sierra Leonean LASV
lineages would lead to increased translational output in an
experimental system. Surprisingly, the opposite was true. Niger-
ian LASV lineages had significantly higher in vitro protein outputs
than their Sierra Leonean counterparts (Figures 4G–4I). Transla-
tion-independent mechanisms, such as post-translational mod-
ifications and protein stability, could explain these observations,
regardless of CAI differences.
If the progenitor to Sierra Leone LASV strains indeed had
lower translational output, the emergence of LASV strains with
increased CAI could have been driven by positive selection to
compensate. The higher CAI could then have led to higher
viral titers in human patients. Alternatively, the increase in CAI
could have been caused by genetic drift. Under this scenario,
mutational biases (Supplemental Experimental Procedures)
and drift—combined with insufficient time for mutations to be
exposed to purifying selection in Sierra Leone—led to an
increase in CAI, independently of positive selection. The Sierra
Leonean tMRCA of the LASV population is indeed relatively
recent (Figure 2G), having possibly undergone a recent popula-
tion bottleneck (Lalis et al., 2012). Further work will be required to
disentangle the adaptive and neutral contributions to the evolu-
tion of CAI and determine whether changes in CAI affect viral
fitness and CFRs.
Immune Selection on Lassa Virus within Hosts
The observation that LASV GPC has the highest intrahost dN/dS
(Figure 5E) and the most nonsynonymous iSNVs in predicted
epitopes (Figure 6) suggests that it is a target of immune-
driven diversifying selection within hosts, both in humans and
M. natalensis. This effect was most strongly supported whenCell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc. 747
we investigated the involvement of B cells (Figure 6A), although
we also found weaker evidence for the role of T cells (Figure 6C).
Given that human LASV infections are typically thought to be
of short duration, it is perhaps surprising that there would be
enough time for the host to mount an antibody response, and
for viral diversity to bemeasurably shaped by this selective pres-
sure. However, this is not entirely implausible, since it is known
that LASV-specific antibodies appear relatively quickly, with
experimentally infected nonhuman primates developing detect-
able IgM titers after 9 days and IgG titers after 12 days (Baize
et al., 2009). Furthermore, it has also been shown that 25% of
LF patients in Sierra Leone are IgM-positive upon admission
and 10% are IgG-positive (Shaffer et al., 2014). Combined with
the observation that several LF patients have LASV iSNV
numbers similar to those observed in M. natalensis (Figures 5B
and 5C), sufficient time for antibody-mediated responses has
likely elapsed in a number of LF patients when they present at
the hospital. We were unable to test seropositivity in our cohort,
but future studies could assess whether there is a correlation
between the presence or absence of LASV-specific antibodies
and the number of iSNVs. Our prediction would be that LF pa-
tients with high numbers of LASV iSNVs should also tend to be
IgM- and/or IgG-positive upon admission.
Conclusions
Our dataset of full-length LASV genomes yields insights into the
biogeography, evolution, and spread of a hemorrhagic fever-
causing virus. Further improvements in collecting, sequencing,
and analyzing LASV and EBOV samples combined with concur-
rent experiments in BL-4 laboratories will allow us to pursue
open areas of inquiry. The catalog of LASV genetic diversity pre-
sented here is thus an essential foundation for the development
of vaccines and diagnostics for a highly diverse, continuously
evolving, and unusually prevalent BL-4 agent.
EXPERIMENTAL PROCEDURES
Ethics Statement
Subjects were recruited for this study using protocols approved by relevant
human subjects committees. All patients were treated with a similar standard
of care.
Samples
All samples were acquired on the day of admission before any treatment reg-
imens had begun. 10 ml of whole blood was collected, and plasma or serum
was prepared. Diagnostic tests for the presence of LASV were performed
on-site. Rodents (all from Sierra Leone) were trapped in case households
and humanely sacrificed, and samples were collected from serum and/or
spleen. All samples were inactivated in either Buffer AVL (QIAGEN) or TRIzol
(Life Technologies), following the manufacturer’s standard protocols and
stored in solar-driven 20C freezers.
Case Fatality Rates
CFRs were calculated from patients that had all of the following characteris-
tics: (1) known outcome, (2) positive for LASV in the field, (3) confirmed positive
upon retesting in the United States, and (4) sequencing confirmed the pres-
ence of LASV.
Sequencing
cDNA synthesis and Illumina library construction were performed, libraries
were pooled, and sequenced on the Illumina platform. All the data were depos-748 Cell 162, 738–750, August 13, 2015 ª2015 Elsevier Inc.ited at NCBI (BioProject PRJNA254017). EBOV data are available under
PRJNA257197.
Assembly of LASV Genomes
LASV genomes were de novo assembled, followed by read mapping and
duplicate removal.
Trees
Maximum likelihood phylogenies were made with RAxML (v.7.3.0) (Stamatakis
et al., 2005) and rooted using the 1969 Pinneo strain.
Molecular Dating
BEAST (v.1.7.4) (Drummond and Rambaut, 2007) was used with a model
incorporating a log normal relaxed clock, exponential growth, HKYgi with
four categories, and codon partitioning (srd06).
Intrahost Variants
iSNVs were called and filtered taking into consideration minimum coverage,
minimum frequency (5%), strand-bias, and base quality.
Intrahost Selection
A modified version of the McDonald-Kreitman test (McDonald and Kreitman,
1991) was applied to assess evidence for natural selection.
Epitope Prediction
B cell epitopes were predicted using BCPRED (El-Manzalawy et al., 2008).
T cell epitopes were predicted using NetCTL (Larsen et al., 2007).
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